Mel Gibson Podcast Plug Doubled Ivermectin Cancer Prescriptions Nationwide
A celebrity endorsement on Joe Rogan's podcast caused ivermectin prescriptions for cancer patients to nearly double, highlighting misinformation risks.
Summary
After actor Mel Gibson promoted ivermectin combined with benzimidazole as a cancer cure on the Joe Rogan Experience in January 2025, monthly prescription rates for the combination nearly doubled compared to the same period in 2024. The increase was most pronounced among white men under 65, especially in the South — demographics that closely mirror typical podcast audiences. Researchers from Virginia Tech Carilion and UCLA published findings in JAMA Network Open, warning that celebrity health misinformation can shift prescribing patterns faster than evidence-based medicine ever could. There is currently no strong clinical evidence supporting ivermectin-benzimidazole as a cancer treatment, making this a significant patient safety concern.
Detailed Summary
When Mel Gibson told Joe Rogan's 16-million-subscriber audience that ivermectin combined with benzimidazole could cure advanced cancer, the ripple effect in real-world prescribing was nearly immediate. This study, published in JAMA Network Open, quantifies just how powerful a single celebrity appearance can be in shaping medical behavior — even for serious, life-threatening conditions like cancer.
Researchers analyzed national prescription data and found that monthly prescribing rates for the ivermectin-benzimidazole combination carried a rate ratio of 1.97 for January through July 2025 versus the same months in 2024 — meaning prescriptions essentially doubled. Among patients with confirmed cancer diagnoses, the increase was even more striking, driven heavily by white men under age 65 living in Southern states.
The demographic pattern was not random. The researchers noted it closely mirrors the known audience profile of the Joe Rogan Experience, suggesting that health misinformation doesn't spread uniformly — it travels along existing social and media networks. This selective amplification means certain patient populations are disproportionately exposed to and influenced by unverified health claims.
This isn't the first time ivermectin sparked a prescribing surge based on non-clinical factors. The same research team previously documented similar patterns during COVID-19. The speed of the shift is what alarms clinicians — evidence-based changes in prescribing typically take years, yet this one happened within weeks of a podcast episode.
For health-conscious individuals, the takeaway is sobering: celebrity endorsements can override medical evidence at scale, potentially leading patients with serious diseases away from proven treatments. There is no peer-reviewed clinical evidence establishing ivermectin-benzimidazole as an effective cancer therapy. Patients considering unconventional treatments should consult oncologists and review primary literature before acting on public figure recommendations.
Key Findings
- Ivermectin-benzimidazole prescriptions nearly doubled (RR 1.97) after Mel Gibson's Joe Rogan appearance in January 2025.
- Prescription increases were largest among white men under 65 in Southern states, mirroring podcast demographics.
- Prescribing shifts occurred within weeks — far faster than evidence-based medicine typically influences clinical practice.
- No strong clinical evidence currently supports ivermectin-benzimidazole as an effective cancer treatment.
- Celebrity health misinformation selectively amplifies within specific demographic and regional networks.
Methodology
This is a news report summarizing a peer-reviewed observational study published in JAMA Network Open, a credible open-access medical journal. The study used national prescription data with defined time periods and calculated rate ratios with 95% confidence intervals. The source, MedPage Today, is a reputable medical news outlet targeting clinicians.
Study Limitations
The article is a news summary and does not reproduce the full study methodology or data tables — the primary JAMA Network Open paper should be consulted for complete analysis. The study is observational and cannot determine patient outcomes from off-label prescribing. It is unclear what proportion of prescriptions were initiated by patients versus physician-driven.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.